SK-OV-3細(xì)胞
運(yùn)輸方式： 凍存運(yùn)輸
數(shù)量： 大量
生長(zhǎng)狀態(tài)： 貼壁生長(zhǎng)
細(xì)胞形態(tài)： 上皮樣
是否是腫瘤細(xì)胞： 1
物種來(lái)源： 人
年限： 64 years
ATCC Number： HTB-77?
相關(guān)**： 腺癌
器官來(lái)源： 卵巢
SK-OV-3細(xì)胞Designations: SK-OV-3 [SKOV-3]
Depositors: G Trempe, LJ Old
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens
Morphology: epithelial
Source: Organ: ovary
Disease: adenocarcinoma
Derived from metastatic site: ascites
Permits/Forms: SK-OV-3細(xì)胞In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions: The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439.
Isolation: Isolation date: 1973
Applications: transfection host
Tumorigenic: Yes
Antigen Expression: Blood Type B; Rh+
DNA Profile (STR): Amelogenin: X
CSF1PO: 11
D13S317: 8,11
D16S539: 12
D5S818: 11
D7S820: 13,14
THO1: 9,9.3
TPOX: 8,11
vWA: 17,18
SK-OV-3細(xì)胞Cytogenetic Analysis: This is a hypodiploid human cell line. The modal chromosome number was 43, occurring in 63.3% of cells. The range was 42 to 45. The rate of higher ploidies was 32%. The del(1)(q21), der(13)t(1;?;13) (q11;?;q34), der(11)t(11;?) (q12), del(10)(q22) and 3 other marker chromosomes were common to most cells, and 3 others were found only in some cells. One N11 had the HSR segment from p11 to the distal end. The normal N10, N12, N15, N17 and N19 were absent. Others were either single or paired. There were from 1 to 6 rearranged and unassignable chromosomes. The X chromosome was either single or paired.
Isoenzymes: AK-1, 1
ES-D, 1
G6PD, B
GLO-I, 1-2
Me-2, 1
PGM1, 1-2
PGM3, 1
Age: 64 years
Gender: female
Ethnicity: Caucasian
Comments: SK-OV-3 cells are resistant to tumor necrosis factor and to several cytotoxic drugs including diphtheria toxin, cis-platinum and adriamycin.
Propagation: SK-OV-3細(xì)胞ATCC complete growth medium: The base medium for this cell line is ATCC-formulated McCoy's 5a Medium Modified, Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol:
Remove and discard culture medium.
Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.
Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
Add appropriate aliquots of the cell suspension to new culture vessels.
Incubate cultures at 37?C.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:6 is recommended
Medium Renewal: 2 to 3 times per week
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products: SK-OV-3細(xì)胞Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2007
recommended serum:ATCC 30-2020
References: 21869: . Human tumor cells in vitro. New York: Plenum Press; 1975.
22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871
22539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080
23103: Morimoto H, et al. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res. 53: 2591-2596, 1993. PubMed: 7684321
23478: Morimoto H, et al. Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin- mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J. Immunol. 147: 2609-2616, 1991. PubMed: 1918981
32281: Zhang X, et al. Microfilament depletion and circumvention of multiple drug resistance by sphinxolides. Cancer Res. 57: 3751-3758, 1997. PubMed: 9288783
32456: Clinton GM, et al. Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc. Natl. Acad. Sci. USA 93: 316-320, 1996. PubMed: 8552629
32530: Zhang X, Smith CD. Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance. Mol. Pharmacol. 49: 288-294, 1996. PubMed: 8632761
90272: Wiechen K, et al. Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells. Br. J. Cancer 81: 790-795, 1999. PubMed: 10555747
90273: Yu D, et al. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 53: 891-898, 1993. PubMed: 8094034
90274: Karlan BY, et al. Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. Gyn. Onc. 53: 70-77, 1994. PubMed: 7909787
